window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 28, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

early phase trials

  • Clinical Development,Clinical Trials,Healthcare leadership,Oncology

    START appoints Salwan Al Mutar to lead clinical research in Dallas-Fort Worth

    START has appointed Salwan Al Mutar as director of clinical [...]

    April 10, 2026
  • Clinical Development,Clinical Trials,Global health,Movers & Shakers,Partnerships & Funding,Research & Development

    Nucleus Network acquires Hammersmith Medicines Research to expand global early-phase clinical trial footprint

    Nucleus Network has acquired UK-based Hammersmith Medicines Research (HMR), a [...]

    August 5, 2025
  • Clinical Trials,Oncology,Patient Centricity,Technology and platforms

    START launches Hope Hub to improve access to early-phase cancer trials

    START unveils the Hope Hub, a digital platform connecting patients, [...]

    July 2, 2025
  • Clinical Trials,Drug Development

    START and OneOncology expand access to early phase cancer trials in US communities

    A new partnership will bring early phase clinical trials closer [...]

    May 28, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • ISS National Lab research advances DNA-inspired cancer nanomaterials for chemotherapy and immunotherapy development
    Categories: Drug Delivery & Formulation, Drug Development, Oncology, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
  • Neomorph raises $100 million to advance NEO-811 Phase 1/2 cancer trial and molecular glue degrader pipeline
    Categories: Biotech, Clinical Trials, Drug discovery, Funding, Oncology, Partnerships & Funding, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
  • NICE expands Lokelma access for hyperkalaemia after draft recommendation
    Categories: Cardiovascular diseases, Chronic diseases, Market Access & Commercialization, Pharmaceuticals and therapeutics, Regulatory Affairs
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top